Papers, explained in our own words

1. Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement

Rumiana Tenchov, Robert E. Bird, Allison E. Curtze, Qiongqiong Angela Zhou

Lipid nanoparticles (LNPs) have become key delivery vehicles across pharmaceuticals, with renewed prominence as the delivery platform for COVID-19 mRNA vaccines. The field lacks a broad, quantitative landscape of LNP research across liposomes, solid lipid nanoparticles, nanostructured lipid carriers, cationic…

• Lipid nanoparticle
• mRNA
• Liposomes
• Nanoparticles
• Vaccine delivery
• siRNA
• DNA

2. Nasal Vaccination with Poly(β-amino ester)–Poly(D,L-lactide-co-glycolide) Hybrid Nanoparticles

Genada Sinani, Melike Sessevmez, M. Koray Gök, Saadet Özgümüş, Alper Okyar, H. Oya Alpar, Erdal Cevher

Mucosal vaccination can stimulate both mucosal and systemic immunity, but free protein antigens generally induce poor systemic immune responses and require adjuvants. There is a need for a safe, effective nasal vaccine carrier that improves antigen stability, uptake, and immunogenicity, especially for poorly…

• Nanoparticles
• PLGA
• Poly(beta-amino ester)
• Polymeric
• Viral vectors
• Vaccine delivery
• Nanocarriers

3. Liposomal Formulations in Clinical Use: An Updated Review

Liposomes are the first nano drug delivery systems successfully translated into clinical use, but many formulations still face limitations in biodistribution, toxicity, stability, and target selectivity. An updated review was needed to summarise liposome technologies, marketed clinical products, formulation aspects…

• Liposomes
• Drug delivery
• siRNA
• Targeted delivery
• Vaccine delivery
• Biodistribution
• Nanocarriers

4. Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles

Samar Hamdy, Azita Haddadi, Anooshirvan Shayeqanpour, John Samuel, Afsaneh Lavasanifar

Mannosylation of vaccine formulations is a promising strategy to target antigens to the mannose receptor (MR) on dendritic cells (DCs), potentially improving antigen uptake, processing, and presentation. While PLGA nanoparticles (NPs) are established vaccine delivery vehicles, the effect of chemical conjugation of…

• T cells
• PLGA
• Nanoparticles
• Polymeric
• Dendritic cells
• Vaccine delivery
• Peptides

5. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro

Luis J. Cruz, Paul J. Tacken, Remco Fokkink, Ben Joosten, Martien Cohen Stuart, Fernando Albericio, Ruurd Torensma, Carl G. Figdor

Antibody-mediated targeting of vaccine components to dendritic cells (DCs) enhances vaccine efficacy, but linking multiple antigens and immune modulators to a single antibody is limited. Slow-release PLGA particles conjugated to DC-specific antibodies could overcome this by delivering large antigen payloads and…

• PLGA
• Dendritic cells
• T cells
• Antigen presentation
• Nanoparticles
• Polymeric
• Vaccine delivery

6. Immunoenhancement effects of chitosan-modified ginseng stem-leaf saponins-encapsulated cubosomes as an adjuvant

Qiu T, Gu P, Wusiman A, Ni H, Xu S, Zhang Y, Zhu T, He J, Liu Z, Hu Y, Liu J, Wang D

Conventional adjuvants such as aluminium and Freund’s adjuvants have limitations, including poor cell-mediated immunity and local toxicity. Ginseng stem-leaf saponins (GSLS) have immunomodulatory/adjuvant activity, but improved delivery systems are needed. Cubosomes are stable lipid cubic liquid crystalline…

• Chitosan
• T cells
• Nanoparticles
• Macrophages
• Cellular uptake
• Vaccine delivery
• Biodistribution